LYEL
Lyell Immunopharma Inc
NASDAQ · Biotechnology
$22.71
+0.07 (+0.31%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 99.8K | 558.1K | 112.33M | 107.82M | 110.08M |
| Net Income | -560,513,187 | -2,819,798,034 | -19,714,534 | -16,079,673 | -17,508,845 |
| EPS | — | — | — | — | — |
| Profit Margin | -562,295.1% | -534,180.3% | -17.6% | -14.9% | -15.9% |
| Rev Growth | -82.1% | -82.1% | +21.9% | +2.1% | -2.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 197.39M | 170.75M | 218.79M |
| Total Equity | — | — | 315.89M | 336.15M | 314.14M |
| D/E Ratio | — | — | 0.62 | 0.51 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -567,160,420 | -3,011,751,811 | -21,929,970 | -19,078,562 | -20,059,530 |
| Free Cash Flow | — | — | -8,566,773 | -8,704,547 | -8,409,186 |